Word: cancers
(lookup in dictionary)
(lookup stats)
Dates: all
Sort By: most recent first
(reverse)
Self-examination for signs of skin cancer is simple, requiring little more than a full-length mirror, a hand mirror to see one's back and a blow-dryer to examine the scalp. "The ability of people to detect skin cancers is tremendous if they're motivated," observes Dr. Robert Friedman of N.Y.U. Indeed, many newly motivated Americans went scurrying to dermatologists last week, just as Reagan's colon cancer sent them to gastroenterologists. "We had five patients walk in off the streets who identified their own basal-cell carcinomas," says Friedman. "Four of them were right." --By Claudia Wallis...
Shortly after Ronald Reagan cleared up the confusion about his skin cancer last week, several reporters laced into White House Spokesman Larry Speakes for being less than candid the week before, when he declined to say whether a biopsy had been performed. "You pulled an iron curtain down on the truth," said U.P.I. Correspondent Helen Thomas at a tense briefing. "Exactly right," replied Speakes. "But I did not lie. And I told the truth...
...young biotechnology industry has already shown that it can perform miracles of science, creating marvelous synthetic molecules with the potential to attack cancer or stop heart attacks. Now the genetic engineering companies are out to prove that they can work the same magic in the marketplace, turning those wonder drugs into profitmakers. Last week Genentech, an industry leader based in south San Francisco, began selling its first drug product for humans: Protropin, a growth hormone used to treat dwarfism in children. Genentech had previously developed Humulin, a synthetic insulin, but licensed it to an established pharmaceutical company, Eli Lilly, which...
...join the business is to swallow biotech firms whole. Eli Lilly announced in September that it would pay $300 million for San Diego-based Hybritech, one of the leaders in the development of monoclonal antibodies, which are proteins that could potentially help diagnose and conquer diseases like cancer. Last week Bristol-Myers said it would buy Seattle's Genetic Systems, another specialist in monoclonal antibodies, for $260 million...
...revenues: $6.4 billion) international petroleum-services company, which he expanded from a narrow base in oil-well testing into a conglomerate with holdings in electronic instruments, semiconductors and computer-aided design systems, and forged into what was widely regarded as one of the world's best-managed firms; of cancer; in Paris...